- Home
- MTA vs VNDA Comparison
MTA vs VNDA Comparison
Compare MTA & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | VNDA |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.0M | 289.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | MTA | VNDA |
|---|---|---|
| Price | $7.87 | $6.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.50 | ★ $14.00 |
| AVG Volume (30 Days) | 450.3K | ★ 1.3M |
| Earning Date | 11-13-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,546,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $127.20 | $12.01 |
| Revenue Next Year | $75.15 | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 108.91 | 11.12 |
| 52 Week Low | $2.45 | $3.81 |
| 52 Week High | $8.17 | $6.88 |
Technical Indicators
Market Signals| Indicator | MTA | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 63.55 |
| Support Level | $7.15 | $4.89 |
| Resistance Level | $7.68 | $6.88 |
| Average True Range (ATR) | 0.33 | 0.39 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 85.32 | 70.10 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.